Dai-Qiang Liu

Dr. Dai-Qiang Liu

Department of Anesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
JSJia Sun
Jia Sun
JLJia-Yan Li
Jia-Yan Li
LZLong-Qing Zhang
Long-Qing Zhang
DLDan-Yang Li
Dan-Yang Li
JWJia-Yi Wu
Jia-Yi Wu
WMWei Mei
Wei Mei
Background. Neuropathic pain is a debilitating disease with few effective treatments. Emerging evidence indicates the involvement of mitochondrial dysfunction and oxidative stress in neuropathic pain. Nuclear factor erythroid 2‐related factor 2 (Nrf2) is a potent regulator of the antioxidant response system. In this study, we investigated whether RTA‐408 (RTA, a novel synthetic triterpenoid under clinical investigation) could activate Nrf2 and promote mitochondrial biogenesis (MB) to reverse neuropathic pain and the underlying mechanisms. Methods. Neuropathic pain was induced by chronic constriction injury (CCI) of the sciatic nerve. Pain behaviors were measured via the von Frey test and Hargreaves plantar test. The L4‐6 spinal cord was collected to examine the activation of Nrf2 and MB. Results. RTA‐408 treatment significantly reversed mechanical allodynia and thermal hyperalgesia in CCI mice in a dose‐dependent manner. Furthermore, RTA‐408 increased the activity of Nrf2 and significantly restored MB that was impaired in CCI mice in an Nrf2‐dependent manner. Peroxisome proliferator‐activated receptor‐gamma coactivator‐1alpha (PGC‐1α) is the key regulator of MB. We found that the PGC‐1α activator also induced a potent analgesic effect in CCI mice. Moreover, the antinociceptive effect of RTA‐408 was reversed by the preinjection of the PGC‐1α inhibitor. Conclusions. Nrf2 activation attenuates chronic constriction injury‐induced neuropathic pain via induction of PGC‐1α‐mediated mitochondrial biogenesis in the spinal cord. Our results indicate that Nrf2 may be a potential therapeutic strategy to ameliorate neuropathic pain and many other disorders with oxidative stress and mitochondrial dysfunction.

1 September 2021 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
Ya-Qun ZhouYa-Qun Zhou
Ya-Qun Zhou
WMWei Mei
Wei Mei
XTXue-Bi Tian
Xue-Bi Tian
YTYu-Ke Tian
Yu-Ke Tian
Dai-Qiang LiuDai-Qiang Liu
Dai-Qiang Liu
DYDa-Wei Ye
Da-Wei Ye

1 March 2022 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
Ya-Qun ZhouYa-Qun Zhou
Ya-Qun Zhou
XTXue-Bi Tian
Xue-Bi Tian
YTYu-Ke Tian
Yu-Ke Tian
WMWei Mei
Wei Mei
Dai-Qiang LiuDai-Qiang Liu
Dai-Qiang Liu
DYDa-Wei Ye
Da-Wei Ye

6 February 2024 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
LZLongqing Zhang
Longqing Zhang
LLLin Liu
Lin Liu
DLDanyang Li
Danyang Li
JWJiayi Wu
Jiayi Wu
SGShaojie Gao
Shaojie Gao
WMWei Mei
Wei Mei

21 September 2024 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
LZLongqing Zhang
Longqing Zhang
XDXinyi Dai
Xinyi Dai
DLDanyang Li
Danyang Li
JWJiayi Wu
Jiayi Wu
SGShaojie Gao
Shaojie Gao
WMWei Mei
Wei Mei

30 May 2025 in Molecular Pain
Verified
Journal Article
Open access
LLLin Liu
Lin Liu
DLDan-Yang Li
Dan-Yang Li
LZLong-Qing Zhang
Long-Qing Zhang
SGShao-Jie Gao
Shao-Jie Gao
FSFan-He Song
Fan-He Song
WMWei Mei
Wei Mei
Background: Cancer-induced bone pain (CIBP) is a debilitating complication with few effective treatments. Microglial activation contributes to the progression of CIBP. 2-deoxy-D-glucose (2-DG), a glycolytic inhibitor, could inhibit microglial activation. Its effect on CIBP remains unclear. This study aims to investigate the role of 2-DG in CIBP mice and underlying mechanisms. Methods: In this research, we established a CIBP mouse model by injecting Lewis lung cancer (LLC) cells into the bone marrow of the femur. Relevant pain behaviors were assessed by measuring the paw withdrawal threshold and spontaneous hind limb lifting. Additionally, the glycolysis inhibitor 2-DG was intrathecally administered to treat CIBP in mice. Western blotting and immunofluorescence techniques were employed to analyze microglial activation and M1/M2 phenotype markers in the spinal cord. Results: Our findings demonstrated significant microglial activation and polarization toward the M1 phenotype in the spinal cord of CIBP mice. Intrathecal administration of 2-DG effectively alleviated pain-related behaviors in CIBP mice. Furthermore, this treatment suppressed microglial activation and M1 polarization, while significantly restoring levels of the M2 phenotype. Additionally, 2-DG attenuated the production of pro-inflammatory factors such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), while boosting the secretion of the anti-inflammatory factor (IL-10) in the spinal cord of CIBP mice. Notably, 2-DG effectively suppresses microglia activation and M1 polarization in LPS + IFN-γ-induced BV-2 cells by downregulating CD86, iNOS expression, TNF-α, IL-1β, IL-6 levels while upregulating Arg-1, CD206 expression and IL-10 level. Conclusion: These results suggest that 2-DG ameliorates mechanical allodynia, spontaneous pain and neuroinflammation in the spinal cord of CIBP mice by promoting the transition from the M1 phenotype to the M2 phenotype. This study may provide a novel strategy for the treatment of CIBP.